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Summary The tolerability, anti-tumour activity and pharmacokinetic interaction of high-dose intravenous cyclosporin combined with intravenous
etoposide was evaluated in children. Eighteen patients with recurrent or refractory tumours, all of whom had previously received etoposide, were
treated with a combination of high-dose cyclosporin and etoposide. In 13, cyclosporin was given as a continuous infusion (15 mg kg-' per 24 h
for 60 h) and in five a short 3-hour infusion of 30 mg kg-' day-' on three consecutive days. Pharmacokinetic profiles ofetoposide were determined
with and without cyclosporin. Cyclosporin levels ranged from 1359 to 4835 ng ml-' and cyclosporin increased the median area under the
concentration time for etoposide curve from 7.2 to 12.5 mg ml-' min. The majortoxicity was acute with varying forms of hypersensitivity reactions.
In four cases this was severe. Hyperbilirubinaemia was present in 25 of 32 courses but was of short duration. In 14 courses, creatinine and/or
urea was elevated, but was also transient. Significant hypertension was seen in six courses. Four of 17 patients evaluable for response obtained
a partial response and one showed stable disease. It is concluded that in children given the combination of high-dose cyclosporin and etoposide,
the etoposide dose should be halved in order to achieve an area under the drug concentration-time curve similar to that with etoposide alone. A
continuous infusion schedule of cyclosporin is better tolerated during the period of administration but is associated with similar hepatic and renal
dysfunction to a short schedule. The 24% response rate in children who had previously received etoposide suggests that this may be an effective
method of enhancing drug sensitivity and further phase 11 evaluation is justified.
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The development of drug resistance remains the major obstacle to
cure in paediatric cancer. Although most tumours show an impres-
sive initial response to multiagent chemotherapy, in the case of
non-localized rhabdomyosarcoma or neuroblastoma a significant
proportion will recur. Persisting or recurrent disease may reflect a
chemoresistant clone present from the time ofdiagnosis, or induc-
tion of resistance due to initial chemotherapy. The precise role of
tumour cell membrane drug effleux mechanisms in the develop-
ment of chemoresistance in paediatric cancer is unclear (Chan et
al, 1994a; Pinkerton, 1996). Conflicting data have been published
regarding the possible prognostic significance of the detection of
P-glycoprotein (P-gp) in neuroblastoma and rhabdomyosarcoma,
(Bourhis et al, 1989, 1991; Chan et al, 1990, 1991; Corrias et al,
1990; Kuttesch et al, 1996). Studies in Ewing's and osteosarcoma
have indicated that it may be of significance (Serra et al, 1995;
Stein et al, 1996). Although increased levels ofMDR1 expression
have been shown in neuroblastoma after primary treatment, this
could reflect maturation of tumour rather than induction of
chemoresistance (Bourhis et al, 1989). Moreover, such studies
have been bedevilled by difficulties in standardization of method-
ology for P-gp detection and MDR1 determination (Vergier et al,
1993; Brophy et al, 1994; Guerci et al, 1995).
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In vitro studies using several tumour types, including neuroblas-
toma, have demonstrated the ability ofcyclosporin to enhance sensi-
tivity to a range of chemotherapeutic agents (Fridborg et al, 1994;
Merlin et al, 1994). In myeloma and adult leukaemia, the potential
to influence in vivo chemosensitivity to MDR-related drugs has
been demonstrated (Leyland-Jones et al, 1993; Lum et al, 1993).
Studies with verapamil in paediatric cancer have indicated that there
may be the potential to improve chemosensitivity to etoposide
(Cowie et al, 1995; Cairo et al, 1989). In vitro, cyclosporin is more
effective than verapamil and the current study evaluates the
feasibility of combining high-dose cyclosporin with etoposide.
Chemosensitization is clearly dose related and drug levels that are
effective in vitro can be achieved in vivo but require administration
of doses greatly in excess of those used for standard immunosup-
pression. These doses are inevitably accompanied by some degree
ofrenal or hepatic toxicity. Studies in adults have also demonstrated
a striking effect of cyclosporin on the clearance of both etoposide
(Lum, 1992; Yahanda, 1992) and doxorubicin (Erlichman et al,
1993; Bartlett et al, 1994; Rushing et al, 1994) that have important
implications in protocol design (List et al, 1993; McLeod, 1994).
The schedule used in most previous studies in adults has
involved a continuous infusion with the rationale of maintaining
high modulator levels throughout the periods of divided dose
chemotherapy administration. A short higher dose schedule has
been developed by Chan et al (1994a and b; Theis et al, 1995) in
which the drug is given over a 3-h period. In the present study both
schedules were evaluated.
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Table 1 Patients' characteristics
Number Sex Age Disease Disease status before entry Tumour involvement before Previous chemotherapy
(years) into CSA study entry into CSA study
1 M 14.8 RMS E First relapse Right elbow SIOP MMT89, melphalan/ABMT
2 M 15.8 EWINGS First relapse Lung CSTG, ABMT
3 M 14.8 ALL PD on treatment after second relapse BM, peripheral blood UKALL X D; UKALL R1; cytosine/etoposide
4 M 17 OSTEO PD on treatment after second relapse Lung CDDP/Doxo; CPM/etoposide/HDMTX;
5 M 6.3 RMS E Third relapse Left forearm VAC; etoposide/IFO; verapamil + etoposideNA
6 F 5.6 NBL Non-responder Left adrenal, bone, BM OPEC/OJEC;
7 M 6.2 NBL PD on treatment after second relapse BM, regional N OPEC/OJEC melphalan/ABMT; oral etoposide;
8 F 14.5 RMS A First relapse Pelvic disease SIOP MMT89, melphalan/ABMT
9 F 12.1 RMS A Second relapse Lung SIOP MMT89, melphalan/ABMT,
10 M 9.1 NBL Non-responder Regional N, BM OPEC/OJEC
11 F 12.8 RMS A First relapse Pleural, intraspinal, BM SIOP MMT89, melphalan/ABMT
12 M 7.9 RMS E Eighth relapse Nasolabium IVA; VinCaEpi; SIOP MMT89,
melphalan/ABMT
13 M 4.4 NBL Non-responder Left adrenal, bone, BM Rapid COJEC
14 F 18.7 OSTEO Fourth relapse Lung, bone, liver, heart Doxo + CDDP; oral etoposide; etoposide/IFO
15 M 20.7 RMS E PD on treatment after second relapse Pelvic, lung IVA; rapid CDDP/etoposide;
melphalan/PBSC;
16 M 15.7 OSTEO PD on treatment after second relapse Lung Doxo/CDDP; IFO/etoposide
17 M 5.8 WILMS PD on treatment Pelvic, spermatic cord, lung UKW3; carboplatin/etoposide/CPM
18 M 18 RMS A PD on treatment Left breast, local N, right leg Rapid IFO/etoposide; doxo; oral etoposide
RMS, rhabdomyosarcoma (E, embryonal; A, alveolar); ALL, acute lymphoblastic leukaemia; OSTEO, osteosarcoma; NBL, neuroblastoma; PD, progressive
disease; BM, bone marrow; N, nodes; SIOP, Societe Internationale d'Oncologie Pediatrique; MMT89, carboplatin, epirubicin, vincristine, ifosfamide, actinomycin
D, etoposide; ABMT, autologous bone marrow transplantation; CSTG, ifosfamide, vincristine, actinomycin, doxorubicin, etoposide; UKALL X D, vincristine,
asparaginase, prednisolone, doxorubicin, 6-thioguanine, methotrexate, etoposide, cytosine arabinoside, 6-mercaptopurine; UKALL Rl, vincristine,
asparaginase, dexamethasone, epirubicin, 6-thioguanine, methotrexate, etoposide, cytosine arabinoside, 6-mercaptopurine, cyclophosphamide; CDDP,
cisplatin, doxo, doxorubicin; CPM, cyclophosphamide; HD MTX, high-dose methotrexate; VAC, vincristine, actinomycin D, cyclophosphamide; IFO, ifosfamide;
VA, vincristine, actinomycin D; OPEC, vincristine, cisplatin, etoposide, cyclophosphamide; (C)OJEC, (cisplatin) vincristine, carboplatin, etoposide,
cyclophosphamide; VinCaEpi, vincristine, carboplatin, etoposide; UKW3, vincristine, doxorubicin, actinomycin; PBSC, peripheral blood stem cell
MATERIALS AND METHODS
Eighteen patients with ages ranging from 4.4 to 20.7 years
(median 13.6 years) were enrolled into the study. Three young
adults (18, 18.7 and 20.7 years) were included. There were 13
male patients. At diagnosis ten presented with metastatic disease.
The tumour characteristics at entry and previous treatment are
detailed in Table 1. Fifteen patients had disease at the sites
involved at original diagnosis and three had developed new metas-
tases. All tumours had progressed on chemotherapy or had
recurred after primary or salvage chemotherapy. All had failed to
achieve sustained responses to conventional chemotherapy
containing one or more drugs associated with MDR, in particular
etoposide. Patients were excluded if they presented with impaired
liver function, hyperbilirubinaemia or a glomerular filtration rate
less than 60 ml min-' 1.73 m-2.
Before enrolment in the study, haematological, biochemical,
hepatic and renal function were assessed. One patient had persis-
tent thrombocytopenia 3 months after autologous bone marrow
transplantation.
All patients had previously received etoposide with differing
doses and schedules. The median total dose administered was
1800 mg m-2 (range 900-4200). In five, disease had progressed
while on etoposide therapy, in the others it had recurred off treat-
ment. The median interval between exposure to previous etopo-
side and enrolment was 2.5 months.
All patients were closely observed as inpatients during each
treatment course, with 4 hourly blood pressure and pulse moni-
toring. Each patient was weighed daily. Serum biochemistry
including liver function and renal function were assessed daily.
The first two patients were not given antiemetics. Both developed
WHO grade 3 nausea and emesis, and all subsequent patients were
electively given i.v. ondansetron 6-12 hourly. Any pain was
treated with i.v. or oral opiates. Clonidine (selected to avoid inter-
action with cyclosporin) was administered if the diastolic blood
pressure rose above the 90th centile for height. Patients had
weekly blood counts with reassessment of renal and hepatic func-
tion petween courses oftreatment.
The study was approved by the Committee for Clinical
Research and the Royal Marsden Ethics Committee. Written
informed consent was obtained from parents or from patients ifold
enough.
Study design
All patients were scheduled to receive a single dose of etoposide
(150 mg m-2) to document pharmacokinetic profile followed 1-2
weeks later by two courses ofetoposide combined with high-dose
cyclosporin. Disease was reassessed 2-3 weeks after the second
course. The interval between courses was 21 days unless toxicity
necessitated a delay.
Cyclosporin was given as a loading dose of 5 mg kg-' infused
over 2 hours followed by a continuous infusion of 15 mg kg-'
day-' for 60 h (schedule A). This regimen was used in 13 patients.
A further five patients were treated by the short high-dose regimen
described by Chan et al (1994) (Theis et al, 1995) and received
30 mg kg-' infused over 3 hours daily on 3 consecutive days
(schedule B).
In patients receiving the continuous infusion, blood samples
were taken for cyclosporin levels after the loading dose and every
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24 h. In patients receiving the short infusion, several data points
were collected to determine the peak concentration and rate of
elimination within 24 h. Serum cyclosporin levels were estimated
using the enzyme multiplied immunoassay test (EMIT) assay.
Etoposide was given as 150 mg m-2 over 1 hour for 3 days,
commencing 1 hour after the beginning of cyclosporin. Serum
etoposide levels were scheduled to be determined on day 1 at +1,
1.5, 2, 3, 4, 5, 8, 12, 18 and 25 h. At least seven time points per
patient were taken. Samples of serum were stored at -20°C until
assayed at the Cancer Research Unit, Newcastle.
Plasma concentrations of etoposide were measured by high-
performance liquid chromatography using a previously published
method (Millward et al, 1995).
For both drugs, all samples were taken by a single operator from
a double-lumen central line, using a different lumen than that used
for drug infusion. If a drug infusion was in progress at the time of
sampling, it was discontinued and 10 ml of normal saline flushed
through the sampling lumen before withdrawing a specimen.
The pharmacokinetics of etoposide in the presence and absence
of cyclosporin A were calculated by non-compartmental analysis.
Area under the plasma concentration-time curve (AUC) was calcu-
lated by the trapezoidal rule, with extrapolation to infinite time.
Clearance (Cl) and volume ofdistribution at steady state (Vdss) were
calculated using standard methods (Gibaldi and Perrier, 1982).
Terminal elimination rate constant and thus half-life were deter-
mined from log-linear regression of the last four data points. When
etoposide from the previous dose was detectable in the zero time
sample, the AUC was corrected accordingly.
Data from pairs of doses with and without cyclosporin A were
compared using the paired Student's t-test.
Response evaluation
Disease was assessed at baseline using appropriate imaging tech-
niques [ultrasound, computerized tomography scan or magnetic
resonance imaging (MRI)] and metastatic disease using bone
marrow aspirates and trephines. Disease was reassessed after two
courses ofcombined etoposide/cyclosporin with the same imaging
or investigational modalities. Responses were defined as PR,
reduction in all measurable disease of 50% or greater; mixed
response (MR), partial response at one or more of several disease
sites; stable disease (SD), up to a 50% reduction or < 25% increase
at involved sites. Progressive disease (PD) was defined as a 25%
or more increase in the size ofexisting tumour or the development
ofany new lesions.
RESULTS
A total of 32 courses of cyclosporin and etoposide were adminis-
tered. Fourteen patients received two courses, but four were with-
drawn after the first course because of progressive disease. In one
patient, cyclosporin A was administered as a continuous infusion
in the second course after an allergic reaction during the first short
infusion regimen. In two patients, the infusion of cyclosporin was
prolonged from 3 to 6 h because ofan early sensitivity reaction.
Toxicity
In nine patients ten courses ofcyclosporin A were associated with
hypersensitivity reactions. In six cases the reaction was mild (tran-
sient rash and fever < 38.5°C), in three severe (rash, fever and
Table 2 Adverse events by cyclosporin A schedule
Schedule A Schedule B
(number of courses) (number of courses)
Total number of courses
Adverse reaction
Mild/moderate
Severe
Pain requiring opiatesa
Nausea or vomiting
(despite antiemetics)
Renal impairment
Creatinine
Urea
Decline of GFR
Hyperbilirubinaemia
Hypomagnesaemia
Mucositis
Constipation
Hypertension
Fluid retention
Neutropenia < 500
Thrombocytopenia
Infections
24
3
2
6 in 4 patients
11
10
5
6
2
20
20
2
1
5
3
13
6
10
8
3
2
2 in 2 patients
5
4
4
2
5
5
7
3
4
aTwo patients for each group suffered from pain before entry into the study.
bronchospasm) and in one very severe (rash, fever, bronchospasm
with concomitant hypotension). Two further children experienced
facial flushing and one experienced burning fingers during
cyclosporin A infusion.
Eight episodes ofpain requiring opiates occurred in six patients.
In four of them discomfort was already present before
chemotherapy, but in two it became worse during cyclosporin A
infusion. Pain was short lived and persisted after treatment only in
one patient and was related with progressive tumour. The discom-
fort was generally referred to lower extremities and trunk and
known sites of disease were not specifically involved.
Renal impairment (an increase in creatinine and/or urea)
occurred after 14 courses in ten patients. Although such changes
were mild (maximum WHO grade 2) and in most patients values
recovered by the following course, a decline in glomerular filtra-
tion rate (GFR) was documented in four patients after the first two
courses.
Hyperbilirubinaemia was present in 25 courses (range 18-
150 ,umol/l-', median 25), with WHO grade IV toxicity occurring
in four patients. Elevation of bilirubin generally appeared early
during treatment and recovered a few days after the end of drug
administration.
Hypomagnesaemia (less than 6.5 mmol 1-') occurred in 25
courses (less than 0.5 mmol 1-' in three children) and magnesium
supplementation was required after 12 courses.
Hypertension requiring antihypertensive management occurred
during six courses, but was always short lived and responded
promptly to clonidine.
Myelosuppression with grade IV neutropenia was observed
after 20 courses and thrombocytopenia after nine courses. Twelve
patients developed at least one episode of fever or microbiologi-
cally proven infection.
Other events include headache (seven patients), hypokalaemia
(four), mild fluid retention (three), constipation (one) and blurred
vision (one).
British Journal of Cancer (1998) 77(12), 2304-2309 0 Cancer Research Campaign 1998High-dose cyclosporin with etoposide in children 2307
Table 3 Etoposide pharmacokinetics with and without concurrent cyclosporin infusion
Area under drug Clearance Half-life
concentration curve (mg ml-1 min) (ml min-') (min)
Patient Cyclosporin AUC- AUC+ Cl- Cl+ t1/2- tl/2+
schedule
1 A 8.1 14.6 28.5 15.7 196 305
2 A 10.2 26.2 22.0 8.6 206 557
4 A 8.6 16.9 36.5 18.6 305 345
5 A 3.8 7.9 30.2 15.2 120 189
6 A 6.6 8.8 15.9 11.9 165 229
7 A 5.3 10.7 21.9 10.8 103 283
8 A 3.6 10.1 27.2 9.9 123 414
9 B 6.4 16.4 25.8 10.0 208 294
10 B 5.8 14.2 28.6 11.6 82 416
11 B 7.4 14.3 32.5 16.2 176 314
13 B 6.7 13.1 15.3 7.8 148 296
14 A 7.7 15.8 29.3 14.3 154 401
15 A 7.7 12.9 38.1 22.6 258 407
17 A 9.3 13.4 29.1 20.2 231 367
18 A 17.1 21.5 12.8 10.1 616 681
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Figure 1 Plot of etoposide plasma concentration against time for a representative patient. Pharmacokinetics were studied on two occasions, the first with
etoposide administration alone and a second with concomitant administration of cyclosporin, -o-, + CsA; - x -, - CsA
Toxicity according to cyclosporin schedule is described in Table
2. Acute toxicity was less common with the continuous infusion
(21Y% of courses) compared with the shorter regimen (62%), but
overall there were no significant differences between schedules.
Response
One patient with a nasal tumour was not evaluable for response
because post-operative oedema on MRI after incomplete resection
was difficult to distinguish from tumour. In 4 out of 17 patients
(23%) a PR was documented. Two tumours were neuroblastoma,
one rhabdomyosarcoma and one Ewing's sarcoma. One
responding patient with embryonal rhabdomyosarcoma had previ-
ously responded to treatment with verapamil/etoposide but had
progressed at the primary site. One with neuroblastoma was
initially treated with etoposide as part ofmultiagent chemotherapy,
then received oral etoposide without response. The second patient
with neuroblastoma was resistant in bone marrow and bone to an
etoposide-containing regimen.
In ten patients who either responded or had stable disease, 28
more courses of cyclosporin A and etoposide were administered
combined with different drugs (vincristine in 24, actinomycin D in
seven and epirubicin in six) and one of these patients, with
rhabdomyosarcoma, showed a late PR. Three patients achieved
complete remission with subsequent radiotherapy, surgery and
surgery + radiotherapy respectively. All have subsequently relapsed.
Plasma cyclosporin concentration
In patients receiving schedule A, cyclosporin concentration was
measured in 13 patients, at least twice per course. During the first
course, levels afterthe loading dose varied from 1359 to 4835 tg ml'
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and in almost all cases remained above 1000 tm mlP' at steady state
(blood sample taken after 20 and 44 h). Only three children showed
values between 800 and 1000 tg ml after 20 h ofinfusion, but in all
these the level was above 1000 ,tg ml-' after 44 h. Levels 6-8 h after
the end ofthe infusion ranged from 132 to 1900 ,ug ml'. Values in the
second course were very similar.
After the short high-dose infusion ofcyclosporin A (regimen B),
levels were very high after 1 h (9360-30 000 tg ml-') and ranged
from 2270 to 4200 .tg ml' after 6-8 h and less than 1000 ng ml'
after 21 h (680-930 ,ug ml-'). After 24 h cyclosporin A levels were
still appreciable with values ranging from 239 to 1480 ng ml-'.
Etoposide pharmacokinetics
Etoposide levels were analysed in 15 patients after administration
with and without cyclosporin. Details of area under concentration
curve, clearance and half-life of etoposide are shown in Table 3.
With cyclosporin there was a significant increase in AUC (mean
change +89%, P < 0.001) and decrease in clearance (mean change
-48%, P < 0.001). Half-life was significantly increased (mean
change + 78%). Representative plasma concentrations are plotted
in Figure 1. These effects were the same whether the short or the
prolonged cyclosporin A infusion was used. The percentage
increase in AUC for a 24-h infusion ranged from 26% to 180%
(mean 89%) and a 3-h infusion from 34% to 156% (mean 106%).
DISCUSSION
In vitro studies have shown cyclosporin A, at concentrations above
1000 ng ml-', to be one of the more effective modulators of MDR.
The very high drug concentrations used in vitro can be achieved in
vivo, but are limited by the associated toxicity. Although signifi-
cant toxicity may be acceptable in limited centre use, particularly
if only one or two courses are given, the tolerance of a chemosen-
sitizer must be appropriate for use on a multicentre basis and with
repeated courses ofchemotherapy given over several months. This
has been the major reservation regarding the use of verapamil or
norverapamil when inpatient monitoring has been required.
It is apparent from this study that children tolerate, with few
complications, doses of cyclosporin A that in adults have often
produced severe jaundice and renal dysfunction. Although tran-
sient jaundice or changes in urea and creatinine were seen, these
were rarely severe. The main problem was acute toxicity as previ-
ously reported (Theis et al, 1995) with the intravenous preparation
of cyclosporin. This occurred despite adequate mixing of the infu-
sion solution and would preclude its use on an outpatient basis in
the majority of children. Close attention is required to allow early
intervention, with sedation, antihistamines and antiemetic drugs to
avoid unacceptable symptoms. However, as most of the intensive
chemotherapy regimens with which this drug might be combined
would probably be given as an inpatient this should not preclude
its use.
As might have been expected, the serum drug level profile for
cyclosporin was very different for the two schedules given. Very
high concentrations were achieved after the short 3-h infusion, with
levels between 5000 and 15 000,g ml' being maintained for
several hours. With the continuous infusion schedule, levels were
generally between 1000 and 3000 tg ml'. These differences
appeared to result in a higher incidence ofacute toxicity for the short
schedule but had little impact on the subsequent renal or hepatic
toxicity. The very high cyclosporin levels with a short infusion
also appeared to be associated with more marked haematological
toxicity. Seven ofeight patients had an absolute neutrophil count of
0.5 x 1091- compared with 13 of 24 receiving the continuous infu-
sion regimen. As all patients did not have full pharmacokinetic
studies, it is difficult to draw any conclusion whether it was associ-
ated with difference in etoposide levels or enhanced myelosuppres-
sion due to the effect on P-gp expressing haematological precursor
cells. From a practical point of view, particularly in patients with
only a single-lumen central line, or peripheral venous access, the
short 3- to 6-h infusion is preferable. This avoids having to break
into the infusion time for several hours for administration ofcombi-
nation chemotherapy, thus lowering the level of cyclosporin. With
the short infusion, levels are lower 10-24 h after administration, but
the need for prolonged exposure to modulator after chemotherapy
has never been clearly demonstrated.
The effect of high-dose cyclosporin on etoposide clearance is
similar in children to that previously reported in adults and has major
implications forits use in combination chemotherapy regimens (Lum
et al, 1993; McLeod, 1994). With single-agent etoposide the addi-
tional toxicity due to a doubling of the AUC was not a significant
problem, but this would not be the case when added to other myelo-
suppressive chemotherapy. It would seem logical to follow the adult
guidelines and reduce the dose of etoposide by 50%. A similar
adjustment should be made to both doxorubicin, vincristine and
probably actinomycin D (Cowie and Pinkerton, 1994).
This study was primarily designed to evaluate the toxicity ofthe
schedules and their ability to achieve potentially useful levels of
cyclosporin A and not to determine effectiveness of an MDR
reversal strategy. It was of note, however, that with the combina-
tion four patients achieved a partial response. In two of these,
disease had proven resistant to standard-dose etoposide. In the
other two responding patients, although the time from previous
etoposide exposure was long, the duration of response after
cyclosporin/etoposide was longer than that of the previous remis-
sion. Because of the design of this study a possible benefit from
the increased AUC of etoposide cannot be excluded. Subsequent
phase II evaluation of this strategy should allow for this with an
appropriate dose reduction.
There is an urgent need to evaluate new treatment strategies in
poor prognosis paediatric cancer, and the next step should be to
assess the impact of cyclosporin on tumours that are clearly refrac-
tory to prior drug exposure. To formally demonstrate sensitization
of chemotherapy, patients in whom the tumour has failed to
respond to treatment would need to be given the same drugs, but
combined with cyclosporin A, having adjusted the doses to allow
for pharmacokinetic interactions. We are currently piloting a
combination of etoposide, vincristine and epirubicin (EVE) with
cyclosporin A before a phase II trial in which patients with
relapsed tumours will receive a single course ofEVE and, ifshown
to be non-responsive cyclosporin A will be added. Evidence of
chemosensitization from such a phase II study could lead to a
phase III comparison of such chemotherapy with or without
cyclosporin A in poor prognosis neuroblastoma or rhabdomyosar-
coma. In the longer term, alternative, less toxic and perhaps more
effective, modulating agents such as the cyclosporin analogue PSC
833 or the novel agent VX-710 may supersede cyclosporin A
(Helson et al, 1994; Germann et al, 1997; Boote et al, 1996).
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